NEW YORK (GenomeWeb News) – UK-based contract research and synthetic DNA firm SpheriTech said today that it has received an investment of an undisclosed sum from an anonymous angel investor.

The company is using the funds, which it said is in the six-figure range, to hire additional staff and to attract other investors and win government research grants or loans.

"For a company like ours to get off the ground, it's absolutely essential to secure government finance," SpheriTech CEO and Founder Don Wellings said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.